INTRODUCTION {#sec1-1}
============

Primary acquired melanosis (PAM) of the conjunctiva appears as a flat, brown pigmented lesion in the conjunctival epithelium. PAM with atypia is the most important precursor for conjunctival melanoma and its rate of of progression to malignant melanoma has been reported up to 46%.\[[@ref1]\]

The most commonly used treatments for PAM with atypia include surgical excision with cryotherapy and topical mitomycin C (MMC) or interferon-α2b (IFN-α2b).\[[@ref2]\] MMC and IFN-α2b are not only effective for treating conjunctival melanocytic tumors, but also have been used successfully for treatment of conjunctival squamous neoplasia, including conjunctival/corneal intraepithelial neoplasia (CIN) and squamous cell carcinoma (SCC).\[[@ref2]\]

IFN-α2b was used for patients with CIN or SCC of conjunctiva in whom intolerance or recurrence of the tumor developed under treatment with MMC.\[[@ref3][@ref4][@ref5][@ref6][@ref7]\] However, to the best of our knowledge, combined use of MMC and IFN-α2b for treatment of conjunctival melanocytic tumors has not been reported yet.

CASE REPORT {#sec1-2}
===========

A 75-year-old man presented with extensive brown pigmented lesions of the conjunctiva in his left eye. On examination, visual acuity was 6/10 with pseudophakia in the right eye and 2/10 with 3+ nuclear sclerosis in the left eye. Fundus examination was unremarkable in both eyes. The lesion involved the whole bulbar and palpebral conjunctiva extending into the upper and lower fornices. Near the superotemporal limbus, a nodular portion of the lesion seemed to be encroaching onto the cornea. No further abnormal findings were seen on slit lamp examination in both eyes.

Map biopsy confirmed PAM with atypia especially in the nodular part of the lesion \[Figure [1a](#F1){ref-type="fig"}--[c](#F1){ref-type="fig"}\]. Treatment was initiated with two courses of topical chemotherapy each lasting for 2 months composed of three cycles MMC 0.04% eye drops every 6 h. The first cycle lasted for 3 weeks followed by a 1-week gap to allow the ocular surface to recover, then the second cycle was initiated for 2 weeks followed by another 1-week treatment gap of MMC and finally, MMC was administered again for 1-week. After 1-month of rest, the second 2-month episode of treatment with MMC was implemented as described above. The lesion decreased in size and pigmentation in the middle of the second course of therapy \[Figure [1d](#F1){ref-type="fig"}--[f](#F1){ref-type="fig"}\].

![Therapeutic trend of our patient with extensive primary acquired melanosis (PAM) in the left eye treated with topical mitomycin C (MMC) and interferon (INF) α-2b; (a-c), appearance of the eye at presentation: Histologically confirmed PAM with atypia involved the bulbar and palpebral conjunctiva as well as the superotemporal cornea; (d-f), relative response to therapy in the middle of the treatment, note decreased size and pigmentation of the lesion; (g-i), Final result of treatment after receiving MMC followed by 6 months of therapy with INF-α2b; (j-l), Appearance of the ocular surface after another year of follow-up, note more significant dilution of residual pigmentation without treatment.](JOVR-10-84-g001){#F1}

The second course of MMC therapy was interrupted in its final week because of severe discomfort of the patient. Thus, IFN-α2b (1 million units/ml) eye drops were initiated every 6 h for 6 months, during which no significant topical or systemic side effect occurred \[Figure [1d](#F1){ref-type="fig"}--[f](#F1){ref-type="fig"}\]. After 4 months, due to residual pigmentation close to the limbus and on the superior tarsal conjunctiva, the patient received INF-α2b eye drops for more 3 months. No significant complications and no recurrence of the tumor were noted over 24 months follow-up \[Figure [1g](#F1){ref-type="fig"}--[l](#F1){ref-type="fig"}\]. The cataract was operated at this point of time and visual acuity was 7/10 at final follow-up.

DISCUSSION {#sec1-3}
==========

Topical chemotherapy with MMC for conjunctival melanoma was introduced by Finger *et al* This approach offers potential benefits over surgery including less dependence on surgical margins, direct delivery of a high concentration of the chemotherapeutic agent to the tumoral tissue, treatment of tumor extension on the cornea and comfortable repetition.\[[@ref8]\]

Finger *et al* used topical IFN-α2b for PAM for the 1^st^ time.\[[@ref9]\] The agent incurs low toxicity to the ocular surface\[[@ref10][@ref11]\] and as compared to MMC, imposes a lower risk of complications such as corneal erosions, pain, conjunctivitis, punctal occlusion and scleral melting.\[[@ref5]\] Over a mean follow-up period of 15-24.8 months\[[@ref10][@ref11]\] and 15 months,\[[@ref10]\] complete clinical regression was reported in all treated patients except one subject with no systemic side effects.

Some investigators have used IFN-α2b for patients with conjunctival CIN or SCC after intolerance to therapy or tumor recurrence following the application of MMC.\[[@ref3][@ref4][@ref5][@ref6][@ref7]\] Since MMC toxicity is dose-dependent,\[[@ref3]\] replacing it with an effective topical medication with fewer side effects such as IFN-α2b seems rational.

To our knowledge, the patient presented herein, is the first reported case of PAM successfully treated with topical MMC followed by long term topical IFN-α2b. Further studies with larger sample size using such combined therapy as primary treatment for PAM and conjunctival melanoma are recommended.
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